No Data
No Data
Buy Rating Affirmed for Werewolf Therapeutics With Anticipated Surge on WTX-124 Phase 1 Data Release
Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Werewolf Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Werewolf Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Maldonado maintains Werewolf Therapeutics with a Buy and maintains $15 price target.
Buy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform Developments
Recap: Werewolf Therapeutics Q4 Earnings
Werewolf Therapeutics (NASDAQ:HOWL) reported its Q4 earnings results on Thursday, March 7, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsWerewolf Therapeutics beat
No Data